Driving the Development of RNA Therapeutics

Genedata Biologics^® accelerates the design and development of RNA therapeutics and vaccines end-to-end, including RNA/DNA optimization for effectiveness and stability, and development of the most suitable delivery system to increase its durability and reliable target tissue delivery.

Novel mRNA Vaccines

Genedata Biologics scalable and customizable data architecture enables the registration, testing and evaluation of nucleic acid-based therapeutics and vaccines at every stage of development. End-to-end capture of data relating to design, production, testing, and quality control increases the efficiency and throughput. Genedata Biologics facilitates registration of modified nucleosides and the automatic computation of associated physicochemical properties. In addition, delivery system information is captured and tracked, e.g., lipid composition in LNPs. Combined with powerful screening workflow tools for formulation development and functional characterization, the platform delivers critical data infrastructure to realize the promise of RNA therapeutics.

Learn More

Target RNA product molecules, sequence information and modifications can be registered in the system individually or in bulk.

RNA production operations can be tracked, managed and delegated with seamless and robust information transfer across specialized groups and sites.

Formulation, sequence, composition, status and production history of every RNA batch is stored and traceable across the organization.

Formulation information can be seamlessly connected to quality control data and functional assay results to expedite optimization decisions.

1 / 4

Want to Speed Up Discovery of RNA-Based Therapies?

Get Started